• Males and females between 18-75 years of age inclusive(including boundary values).

• Must have had a liver biopsy proven NASH within 6 months or in screening test. The following two requirements must be met at the same time: ① a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components: Steatosis≥1, Lobular inflammation≥1, Ballooning degeneration≥1;② fibrosis stage 1 to 3.

• Must have confirmation of ≥ 8% liver fat content on magnetic resonance imaging- proton density fat fraction (MRI-PDFF) at screening.

• No alcohol consumption or history of excessive alcohol consumption: less than 210 g of ethanol per week for men and 140 g for women in the past 12 months.

• Patients who are taking chronic drugs(including but not limited to antihypertensive drugs, antiatherogenic drugs, oral hypoglycemic drugs, insulin) need to have a steady dose for at least 3 months before liver biopsy.

• Weight was stable(the change is no more than 5%) during the 6 months prior to Screening.

• No attempt to change lifestyle (diet and/or exercise) during the 3 months prior to Screening.

• Ability to understand the requirements of the study and willingness to provide written informed consent.

• Have no pregnancy program and take effective contraceptive measures voluntarily.

⁃ Abide by the experimental protocol and cooperate with the data collection according to the researcher's judgment.